Vaccine interchangeability: problems and prospects

Vaccines by different manufacturers are available for most of the vaccine-preventable infections covered by the National Immunisation Schedule of the Russian Federation. Determination of the possibility of replacing a vaccine in the case of routine or emergency vaccination still remains a challenging issue. The aim of the study was to substantiate the problem of vaccine interchangeability, outline specific challenges and ways of solving them, analyse criteria underlying evaluation of vaccine interchangeability in Russia, and international experience in this area. The procedure for determining the interchangeability of biological products, including vaccines, was established in the Decree of the Government of the Russian Federation of 5 September 2020, No. 1360 “On the procedure for determination of interchangeability of medicinal products for human use”. The paper analyses the applicability of the official criteria for interchangeability of biological products, including vaccines. It outlines the main problems of performing evaluation of vaccine interchangeability in accordance with the established criteria. It is concluded that the vaccine interchangeability criteria need to be clarified in order to allow for assessment of comparability of active substances, and comparison of efficacy, safety, and immunogenicity of vaccines, taking into account vaccination schedules for different age groups. The possibility of evaluating interchangeability based on the results of post-authorisation studies also needs clarification. It is also necessary to align patient information leaflets for interchangeable vaccines.

1. Snegireva II, Zatolochina KE, Darmostukova MA, Alyautdin RN, Romanov BK. Modern approaches to vaccine interchangeability. Vedomosti Nauchnogo tsentra ekspertizy sredstv meditsinskogo primeneniya = The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. 2016;(4):3–8 (In Russ.)

2. Khotova TYu, Snegireva II, Darmostukova MA, Zatolochina KE, Ozertskovskiy NA, Shalunova NV, Romanov BK. The interchangeability of vaccines against viral hepatitis B for immunization of adults. Rossiyskiy meditsinskiy zhurnal = Medical Journal of the Russian Federation, Russian Medical Journal). 2016;22(2):85–90 (In Russ.)

3. Plotkin SA. Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis. 2008;47(3):401–9. https://doi.org/10.1086/589862

4. Alekseeva IA, Perelygina OV. Comparative analysis of whole-cell and acellular pertussis vaccines efficacy in preventing pertussis. BIOpreparaty. Profilaktika, diagnostika, lechenie = BIOpreparations. Prevention, Diagnosis, Treatment. 2017;17(4):207–15 (In Russ.)

5. Medunitsyn NV, Olefir YuV, Merkulov VA, Bondarev VP. Vaccination contribute to the development of personal and herd immunity. BIOpreparaty. Profilaktika, diagnostika, lechenie = BIOpreparations. Prevention, Diagnosis, Treatment. 2017;16(4):195–207 (In Russ.)

6. Greenberg DP, Lieberman JM, Marcy SM, Wong VK, Partridge S, Chang SJ, et al. Enhanced antibody responses in infants given different sequences of heterogeneous Haemophilus influenzae type b conjugate vaccines. J Pediatr. 1995;126(2):206–11. https://doi.org/10.1016/S0022-3476(95)70546-5

7. Anderson EL, Decker MD, Englund JA, Edwards KM, Anderson P, Mclnnes P, Belshe RB. Interchangeability of conjugated Haemophilus influenzae type b vaccines in infants. JAMA. 1995;273(11):849–53. https://doi.org/10.1001/jama.1995.03520350031024

8. Piazza M, Abrescia N, Picciotto L, Orlando R, Cerini R, Borgia G, et al. Demonstration of the interchangeability of 2 types of recombinant anti-hepatitis-B vaccine. Boll Soc Ital Biol Sper. 1993;69(4):273–80.

9. Bryan JP, Henry CH, Hoffman AG, South-Paul JE, Smith JA, Cruess D, et al. Randomized, cross-over, controlled comparison of two inactivated hepatitis A vaccines. Vaccine. 2000;19(7–8):743–50. https://doi.org/10.1016/s0264-410x(00)00301-7

10. Greenberg DP, Pickering LK, Senders SD, Bissey JD, Howard RA, Blatter MM, et al. Interchangeability of 2 diphtheria-tetanus-acellular pertussis vaccines in infancy. Pediatrics. 2002;109(4):666–72. https://doi.org/10.1542/peds.109.4.666

11. Orsi A, Azzari C, Bozzola E, Chiamenti G, Chirico G, Esposito S, et al. Hexavalent vaccines: characteristics of available products and practical considerations from a panel of Italian experts. J Prev Med Hyg. 2018;59(2):E107–19.

12. Feldman S. Interchangeability of vaccines. Pediatr Infect Dis J. 2001;20(11):523–9. https://doi.org/10.1097/00006454-200111001-00004

13. Greenberg DP, Feldman S. Vaccine interchangeability. Clin Pediatr (Phila). 2003;42(2):93–9. https://doi.org/10.1177/000992280304200201

14. Guevara NJ, Borys D, DeAntonio R, Guzman-Holst A, Hoet B. Interchangeability between pneumococcal conjugate vaccines for pediatric use: a systematic literature review. Expert Rev Vaccines. 2020;19(11):1011–22. https://doi.org/10.1080/14760584.2019.1688148

15. Levi DT, Obukhov YuI, Aleksandrova NV, Volkova RA, Elbert EV, Alvarez Figeroa MV, et al. Identity and stability assessment of BCG vaccine by multiplex PCR. BIOpreparaty. Profilaktika, diagnostika, lechenie = BIOpreparations. Prevention, Diagnosis, Treatment. 2016;16(1):49–54 (In Russ.)

16. Cassidy A, Mossman S, Olivieri A, De Ridder М, Leroux-Roels G. Hepatitis B vaccine effectiveness in the face of global HBV genotype diversity. Expert Rev Vaccines. 2011;10(12):1709–15. https://doi.org/10.1586/erv.11.151

17. Chulanov VP, Semenenko TA, Karandashova IV, Komarova SV, Kostyushev DS, Suslov AP, Volchkova EV. Modern view on the problem of choosing a vaccine against hepatitis B. Epidemiologiya i vaccinoprofilaktika = Epidemiology and Vaccinal Prevention. 2017;16(4):65–72 (In Russ.) https://doi.org/10.31631/2073-3046-2017-16-4-65-72

18. Jose-Abredo A. Some considerations about HBV vaccination among HIV patients from Latin America and the Caribbean. Ann Hepatol. 2019;18(5):656–7. https://doi.org/10.1016/j.aohep.2019.06.005